On August 16, 2023, Frontage Laboratories, Inc., and its subsidiary, Frontage Canada, Inc., successfully acquired Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics, a well-established pharmaceutical contract research organization based in Toronto, Canada, specializes in various services including analytical chemistry, microbiology, toxicology, bioanalytical services, and stability sample storage and testing, along with offering consulting in quality control and assurance.

For over 50 years, Nucro-Technics has served an extensive client base, ranging from major pharmaceutical and biotech companies to smaller organizations in academia and industry trade groups. Operating from a 60,000 square foot state-of-the-art facility, the organization focuses on testing both large and small molecules for medical treatments. It is also known for developing and validating methods and assisting in regulatory submissions, maintaining compliance with GLP and GMP standards.

The acquisition was celebrated by both companies' leaders, emphasizing the enhanced service offerings and strengthened global presence it brings. Dr. Abdul Mutlib, CEO of Frontage, highlighted the strategic alignment of Nucro-Technics' client services with Frontage's culture. Dr. Song Li, Frontage's Founder and Chairman, and John Fanaras of Nucro Technics both acknowledged the acquisition as a significant step in expanding their services and supporting pharmaceutical research and development.

Frontage received legal advice from Borden Ladner Gervais LLP (BLG), while Nucro-Technics was counseled by Dentons and PricewaterhouseCoopers Corporate Finance Inc.